Report

Update: Firmly positioned for growth

Consort Medical is a full-service contract development and manufacturing operation (CDMO) that operates across most areas of the pharmaceutical supply chain. Bespak’s strength in drug delivery devices is complemented by Aesica’s span of services from drug manufacture to finished product packaging. The FY15 results demonstrate that strategic progress is being maintained and the target of sustainable double-digit profit growth over the medium term remains on track. Our valuation is 1,001p to 1,061p.
Underlying
Consort Medical

Consort Medical is a contract development and manufacturing organization (CDMO), providing delivery technologies, formulation and manufacturing solutions for drugs. Co. has two operating divisions: Bespak, which is engaged in the development and manufacture of drug delivery devices, serving pharmaceutical companies with inhaler, auto-injector, nasal and ocular technologies and development and manufacturing services; and Aesica (Drugs), a pharmaceutical CDMO serving pharmaceutical companies with active pharmaceutical ingredient and finished dose formulation development and manufacturing services.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch